CSL Announces Full Year Results
CSL ANNOUNCES A RECORD YEAR OF GROWTH
Melbourne, Australia — 21/08/2002
CSL Limited announced today that it achieved a record 2001-2002 net profit after tax of $123.8m, an increase of 58% over the previous year. Group sales rose by 58% to $1,336.4m producing a profit after tax, before amortisation of goodwill, of $163.6m, an increase of 60% on the previous year’s result.
A significant highlight of this result is that 71% of CSL Group sales were derived from international sales.
The result is in line with the announcement at the half year that the Company expected net profit from ordinary activities would increase 55% to 60% for the full year.
The Directors have declared a final dividend of 22c per share fully franked payable on 10 October, 2002, bringing the total dividend for the year to 34c per share.
CSL’s Managing Director, Dr Brian McNamee, said that one of the key influences on the performance of the Company over the past year had been the significant benefit of the trading operations for the full year of ZLB Bioplasma Inc. Dr McNamee also singled out the operations of JRH Biosciences Inc which achieved another strong year of sales growth of 34%.
Dr McNamee added that he was pleased with the successful integration of the plasma collection centres acquired from Nabi in September last year, recording results consistent with expectations at the time of acquisition.
CSL also announced today that, in response to shareholder requests, it proposes to offer to shareholders the opportunity to subscribe for up to $3,000 worth of additional shares in CSL, the proceeds of which will be used for general corporate purposes. The purchase price for each CSL share offered will be at a 2.5% discount to the volume weighted average price of CSL’s shares during the period of five business days ending on 26 September, 2002. This offer will be limited to shareholders with registered addresses in Australia and New Zealand only. The offer to subscribe will be sent on 10 October, 2002, to persons registered as shareholders on 26 September, 2002, along with their dividend payment.
Analyst Presentation (PDF, 0.27MB) - 21 August 2002
For further information contact:
Dr Brian McNamee
Ph: +61 3 9389 1601
Mr Tony Cipa
Ph: +61 3 9389 1601